EP0531105B1 - Use of felbamate for the manufacture of a medicament for the treatment of neuropsychopharmacological disorders - Google Patents
Use of felbamate for the manufacture of a medicament for the treatment of neuropsychopharmacological disorders Download PDFInfo
- Publication number
- EP0531105B1 EP0531105B1 EP92307952A EP92307952A EP0531105B1 EP 0531105 B1 EP0531105 B1 EP 0531105B1 EP 92307952 A EP92307952 A EP 92307952A EP 92307952 A EP92307952 A EP 92307952A EP 0531105 B1 EP0531105 B1 EP 0531105B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- medicament
- felbamate
- use according
- disease
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
Definitions
- the present invention relates to use of 2-phenyl-1,3-propanediol dicarbamate (felbamate) for treating and controlling the symptoms of the neurodegenerative disorders Guam ALS, Parkinsons disease, Alzheimers disease, dementia and lathyrism which are associated with or result from excessive activation of the strychnine-insensitive glycine receptor sites of the N-methyl-D-aspartate receptor complex.
- felbamate 2-phenyl-1,3-propanediol dicarbamate
- glycine modulates excitatory neurotransmission in the central nervous system. These actions are mediated through strychnine-insensitive glycine receptors with markedly different structural requirements for ligand binding and regional distribution than strychnine-sensitive sites associated with the role of glycine as an inhibitory neurotransmitter.
- Neurotransmissions mediated through the N-methyl-D-aspartate (NMDA) receptor supramolecular complex are believed to be associated with numerous pathologic and physiologic mechanisms which include: kindling development, ischemic neuronal injury, synaptogenesis, spatial learning and long-term potentiation. Regulation of these neuronal mechanisms by NMDA-mediated processes is believed to involve activation of a receptor-gated ion channel.
- NMDA N-methyl-D-aspartate
- NMDA complex is regulated, at least in part, by the amino acid glycine.
- Glycine has been shown to increase NMDA evoked currents in various tissues by increasing the opening frequency of the NMDA channel.
- NMDA-induced influx and intracellular accumulation of calcium are stimulated by glycine, which interacts with its own distinct site on the receptor. It is believed that the accumulation of intracellular calcium is implicated in the various neuropathologies.
- US-A-4978680 describes the use of felbamate in the prophylactic treatment of epileptic seizures.
- felbamate interacts with strychnine-insensitive glycine receptors and that neuroprotective effects of felbamate are at least in part mediated through a strychnine-insensitive glycine receptor mechanism.
- Felbamate is a well-known pharmaceutical compound having been described together with methods for its manufacture and use in US-A- 2,884,444; US-A-4,868,327; US-A- 4,978,680; US-A- 5,055489; US-A-5,072,056 and US-A- 5,082,861.
- felbamate chemically described as 2-phenyl-1,3-propanediol dicarbamate is a compound which has demonstrated superior properties with respect to the treatment of the neurodegenerative diseases, Guam ALS, Parkinson's disease, Alzheimer's disease, dementia and lathyrism.
- the use of the dicarbamate of 2-phenyl-1,3-propanediol for the manufacture of a medicament for treating and controlling the symptoms of, or for the prevention and control of the neurodegenerative disorders Guam ALS, Parkinsons disease, Alzheimers disease, dimentia and lathyrism which are associated with or result from excessive activation of the strychnine-insensitive glycine receptor sites of the N-methyl-D-aspartate receptor complex in human or other warm blooded animal patients.
- compositions of the present invention may take any of a variety of forms although they are intended primarily for oral use and are suitable for forming into pills, capsules and tablets by well-known practices. Such forms may be dosage unit forms.
- a typical tablet composition comprises 500 milligrams of 2-phenyl-1,3-propanediol dicarbamate intermixed in a dry pulverulent state with suitable solid carriers and diluents.
- Solid carriers and diluents suitable for use include sugars such as, for example, lactose and sucrose; cellulose derivatives such as, for example, carboxymethyl cellulose, ethyl cellulose, methyl cellulose; gelatin including hard and soft gelatin capsules, talc, cornstarch, stearic acid and magnesium stearate.
- Solid carriers and diluents suitable for use include sugars such as, for example, lactose and sucrose; cellulose derivatives such as, for example, carboxymethyl cellulose, ethyl cellulose, methyl cellulose; gelatin including hard and soft gelatin capsules, talc, cornstarch, stearic acid and magnesium stearate.
- the percentage of 2-phenyl-1,3-propanediol dicarbamate in the compositions may be varied over wide limits and the quantity of medicament furnished by each individual tablet or capsule is relatively unimportant since the indicated total daily dose can be reached by administering either one or a plurality of capsules or tablets.
- an effective daily dose of the active ingredient is in the range of from about 100 milligrams to about 5 grams.
- Felbamate (2-phenyl-1,3-propanediol dicarbamate) has a very favourable preclinical profile characterized by a substantial margin of safety (protective index 16.9 - 19.1).
- the ability of felbamate to interact with strychnine-insensitive glycine receptors is demonstrated. More particularly the radio ligand binding to glycine receptors is demonstrated using the antagonist [ 3 H]5,7-dichlorokynurenic acid, commonly referred to as [ 3 H]5,7DCKA which has been reported to bind with high affinity to glycine receptors in rat membranes.
- This radiolabelled compound is particularly suitable for purposes of demonstrating the present invention because of its high affinity and reliability within and between experiments.
- mice Male Sprague-Dawley rats weighing 150-200 g are housed under a 12-hour light/dark cycle with access to food and water ad libitum . Animals are anesthetized with CO 2 and sacrificed by decapitation. Brains are immediately removed and forebrains dissected, weighed and placed in 10 volumes (original wet weight volume) of 5 mM Hepes/4.5 mM Tris buffer (HTS; pH 7.8) containing 0.32 M sucrose. Tissue preparation is performed at about 4°C unless otherwise stated. Tissues are homogenized using a Brinkmann Polytron (setting 6, 30 seconds), diluted to 50 volumes in HTS-sucrose, and centrifuged at 1,000 xg for 10 minutes.
- HTS Tris buffer
- the resultant pellet (P1) is discarded and supernatant centrifuged at 20,000 xg for 20 minutes.
- the resultant pellet (P2) is re-suspended in HTS and centrifuged at 8,000 xg for 20 minutes.
- the supernatant and outer buffy coat (remaining pellet core discarded) is centrifuged at 20,000 xg for 20 minutes.
- the resultant pellet (P2/P3) is resuspended in HTS containing 1 mM EDTA and centrifuged at 20,000 xg for 20 minutes.
- the P2/P3 pellet is resuspended in HTS and the "washing" procedure is repeated two more times.
- the P2/P3 pellet is then re-suspended in 5 volumes of HTS, frozen on dry-ice and stored at -80°C for at least 72 hours prior to binding assay.
- Assays are performed at 4°C using quadruplicate samples in a total volume/tube of 1-ml consisting of: 500 ⁇ l membrane suspension (200-300 ⁇ g protein/assay tube) in 50 mM Hepes-KOH buffer (pH 8.0 at 4°C), 100 ⁇ l [ 3 H]5,7DCKA solution (19-21 nM; specific activity 18.2 Ci/mmol), 100 ⁇ l drug or buffer, and 300 ⁇ l buffer. Glycine or 7-chlorokynurenic acid (100 uM) is used to define .pl70 nonspecific binding. Felbamate, solutions of 10mM and 100 mM, are dissolved in 40-50% and 100% DMSO, respectively, and serial dilutions are performed.
- Binding reactions are initiated by adding the tissue homogenate and terminated after a 15-minute incubation period by rapid filtration through Brandel GF/B filters using a Brandel M-24 cell harvester. This filtration is followed by two 5-ml rinses with ice-cold buffer. Radioactivity is monitored in a Beckman LS 5801 liquid scintillation counter.
- the K 1 estimates for inhibition of [ 3 H]5,7DCKA were: glycine, 284 nM ( Figure 1); felbamate, 289 ⁇ M; and felbamate (mean +/- SEM), 368 +/- 37 ⁇ M ( Figure 2).
- glycine augments NMDA receptor-mediated membrane depolarization and is required for activation of NMD-gated calcium channels. Furthermore, excessive activation of this "supramolecular complex" (e.g., by excitatory amino acids) has been shown to be associated with seizure disorders, ischemic brain damage and other neuropathologies. Compounds such as felbamate that interact at the strychnine-insensitive glycine modulatory site appear to alter the effects of glycine on the NMDA-gated channels. Thus, the data presented here support a mechanism for neuroprotective effects of felbamate via glycine receptor interaction.
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- The present invention relates to use of 2-phenyl-1,3-propanediol dicarbamate (felbamate) for treating and controlling the symptoms of the neurodegenerative disorders Guam ALS, Parkinsons disease, Alzheimers disease, dementia and lathyrism which are associated with or result from excessive activation of the strychnine-insensitive glycine receptor sites of the N-methyl-D-aspartate receptor complex.
- Neurochemical and electrophysiological studies have demonstrated that glycine modulates excitatory neurotransmission in the central nervous system. These actions are mediated through strychnine-insensitive glycine receptors with markedly different structural requirements for ligand binding and regional distribution than strychnine-sensitive sites associated with the role of glycine as an inhibitory neurotransmitter.
- Neurotransmissions mediated through the N-methyl-D-aspartate (NMDA) receptor supramolecular complex are believed to be associated with numerous pathologic and physiologic mechanisms which include: kindling development, ischemic neuronal injury, synaptogenesis, spatial learning and long-term potentiation. Regulation of these neuronal mechanisms by NMDA-mediated processes is believed to involve activation of a receptor-gated ion channel.
- Evidence now available clearly indicates that the NMDA complex is regulated, at least in part, by the amino acid glycine. Glycine has been shown to increase NMDA evoked currents in various tissues by increasing the opening frequency of the NMDA channel. Thus, NMDA-induced influx and intracellular accumulation of calcium are stimulated by glycine, which interacts with its own distinct site on the receptor. It is believed that the accumulation of intracellular calcium is implicated in the various neuropathologies.
- In Arzneimittel Forschung Vol. 40, 1, 1990 pages 511-514 it is stated, on the basis of animal experimentation, that modulators of NMDA - mediated neutrotransmission may have antiepileptic effects.
- Up to the present time, all drugs used in the treatment of neuropsychopharmacological disorders and neurodegenerative diseases function as prophylactics against the symptoms of these disorders and diseases as opposed to being curatives.
- For example, US-A-4978680 describes the use of felbamate in the prophylactic treatment of epileptic seizures.
- In accordance with the present invention, it has been established that felbamate interacts with strychnine-insensitive glycine receptors and that neuroprotective effects of felbamate are at least in part mediated through a strychnine-insensitive glycine receptor mechanism.
- Felbamate is a well-known pharmaceutical compound having been described together with methods for its manufacture and use in US-A- 2,884,444; US-A-4,868,327; US-A- 4,978,680; US-A- 5,055489; US-A-5,072,056 and US-A- 5,082,861.
- It has now been found possible to provide methods and compositions for the treatment and control of the symptoms of the neurodegenerative diseases Guam ALS, Parkinsons disease, Alzheimers disease, dementia and lathyrism.
- Accordingly, in the present invention it has been found that felbamate chemically described as 2-phenyl-1,3-propanediol dicarbamate is a compound which has demonstrated superior properties with respect to the treatment of the neurodegenerative diseases, Guam ALS, Parkinson's disease, Alzheimer's disease, dementia and lathyrism.
- According to the present invention there is provided the use of the dicarbamate of 2-phenyl-1,3-propanediol for the manufacture of a medicament for treating and controlling the symptoms of, or for the prevention and control of the neurodegenerative disorders Guam ALS, Parkinsons disease, Alzheimers disease, dimentia and lathyrism which are associated with or result from excessive activation of the strychnine-insensitive glycine receptor sites of the N-methyl-D-aspartate receptor complex in human or other warm blooded animal patients.
- The compositions of the present invention may take any of a variety of forms although they are intended primarily for oral use and are suitable for forming into pills, capsules and tablets by well-known practices. Such forms may be dosage unit forms. When the active ingredient is in the form of a solid, a typical tablet composition comprises 500 milligrams of 2-phenyl-1,3-propanediol dicarbamate intermixed in a dry pulverulent state with suitable solid carriers and diluents.
- Solid carriers and diluents suitable for use include sugars such as, for example, lactose and sucrose; cellulose derivatives such as, for example, carboxymethyl cellulose, ethyl cellulose, methyl cellulose; gelatin including hard and soft gelatin capsules, talc, cornstarch, stearic acid and magnesium stearate.
- Solid carriers and diluents suitable for use include sugars such as, for example, lactose and sucrose; cellulose derivatives such as, for example, carboxymethyl cellulose, ethyl cellulose, methyl cellulose; gelatin including hard and soft gelatin capsules, talc, cornstarch, stearic acid and magnesium stearate.
- The percentage of 2-phenyl-1,3-propanediol dicarbamate in the compositions may be varied over wide limits and the quantity of medicament furnished by each individual tablet or capsule is relatively unimportant since the indicated total daily dose can be reached by administering either one or a plurality of capsules or tablets.
- In general, an effective daily dose of the active ingredient is in the range of from about 100 milligrams to about 5 grams.
- Felbamate (2-phenyl-1,3-propanediol dicarbamate) has a very favourable preclinical profile characterized by a substantial margin of safety (protective index 16.9 - 19.1).
- The present invention will now be further described with reference to, but is in no manner limited to, the following Example.
- In the Example, the ability of felbamate to interact with strychnine-insensitive glycine receptors is demonstrated. More particularly the radio ligand binding to glycine receptors is demonstrated using the antagonist [3H]5,7-dichlorokynurenic acid, commonly referred to as [3H]5,7DCKA which has been reported to bind with high affinity to glycine receptors in rat membranes. This radiolabelled compound is particularly suitable for purposes of demonstrating the present invention because of its high affinity and reliability within and between experiments.
- Male Sprague-Dawley rats weighing 150-200 g are housed under a 12-hour light/dark cycle with access to food and water ad libitum. Animals are anesthetized with CO2 and sacrificed by decapitation. Brains are immediately removed and forebrains dissected, weighed and placed in 10 volumes (original wet weight volume) of 5 mM Hepes/4.5 mM Tris buffer (HTS; pH 7.8) containing 0.32 M sucrose. Tissue preparation is performed at about 4°C unless otherwise stated. Tissues are homogenized using a Brinkmann Polytron (setting 6, 30 seconds), diluted to 50 volumes in HTS-sucrose, and centrifuged at 1,000 xg for 10 minutes. The resultant pellet (P1) is discarded and supernatant centrifuged at 20,000 xg for 20 minutes. The resultant pellet (P2) is re-suspended in HTS and centrifuged at 8,000 xg for 20 minutes. The supernatant and outer buffy coat (remaining pellet core discarded) is centrifuged at 20,000 xg for 20 minutes. The resultant pellet (P2/P3) is resuspended in HTS containing 1 mM EDTA and centrifuged at 20,000 xg for 20 minutes. The P2/P3 pellet is resuspended in HTS and the "washing" procedure is repeated two more times. The P2/P3 pellet is then re-suspended in 5 volumes of HTS, frozen on dry-ice and stored at -80°C for at least 72 hours prior to binding assay.
- At the time of the assay, the appropriate amount of tissue is thawed and re-suspended in 50 mM Hepes-KOH buffer (pH 8.0 at 4°C) and "washed" twice by re-suspension and centrifugation at 20,000 xg for 20 minutes. The binding of [3H]5,7DCKA is performed as described by Baron et al. Eur J. Pharmacol 206: 149-154 (1991). Assays are performed at 4°C using quadruplicate samples in a total volume/tube of 1-ml consisting of: 500 µl membrane suspension (200-300 µg protein/assay tube) in 50 mM Hepes-KOH buffer (pH 8.0 at 4°C), 100 µl [3H]5,7DCKA solution (19-21 nM; specific activity 18.2 Ci/mmol), 100 µl drug or buffer, and 300 µl buffer. Glycine or 7-chlorokynurenic acid (100 uM) is used to define .pl70 nonspecific binding. Felbamate, solutions of 10mM and 100 mM, are dissolved in 40-50% and 100% DMSO, respectively, and serial dilutions are performed. Binding reactions are initiated by adding the tissue homogenate and terminated after a 15-minute incubation period by rapid filtration through Brandel GF/B filters using a Brandel M-24 cell harvester. This filtration is followed by two 5-ml rinses with ice-cold buffer. Radioactivity is monitored in a Beckman LS 5801 liquid scintillation counter.
- Inhibition of [3H]5,7DCKA binding by glycine (10 nM-10µM) or felbamate (10 µM-10mM) is performed to assess the potencies of these compounds for strychnine-insensitive glycine receptors. Displacement curves and IC50 values were analyzed using Graphpad (ISI Software, Philadelphia, PA). The K1 values were calculated using the equation:
- Displacement of [3H]5,7DCKA by glycine (10 nM 10 µM) yielded an IC50 of 371 nM (Figure 1). Inhibition of [3H]5,7DCKA by felbamate (10 µM-10mM) resulted in an IC50 value of 374 µM (Figure 2). The IC50 shown in Figure 2 is generated by combining and then plotting on a single graph the felbamate displacement data from three separate experiments. A Hill slope (-0.93) of these data demonstrated unity and indicated interaction with a single population of sites. The IC50 value (mean +/- SEM) from the felbamate displacement experiments presented is calculated to be 477 +/- 49 µM. The K1 estimates for inhibition of [3H]5,7DCKA were: glycine, 284 nM (Figure 1); felbamate, 289 µM; and felbamate (mean +/- SEM), 368 +/- 37 µM (Figure 2).
- The IC50 value obtained from glycine inhibition of [3H]5,7DCKA (Figure 1) corresponds well with previously reported data. Moreover, results obtained demonstrate tha felbamate interacts with strychnine-insensitive glycine receptors at relatively high concentrations. These conclusions are based on displacement data illustrating that felbamate competitively inhibits [3H]5,7DCKA) binding to rat forebrain membranes (Figure 2).
- As previously stated, glycine augments NMDA receptor-mediated membrane depolarization and is required for activation of NMD-gated calcium channels. Furthermore, excessive activation of this "supramolecular complex" (e.g., by excitatory amino acids) has been shown to be associated with seizure disorders, ischemic brain damage and other neuropathologies. Compounds such as felbamate that interact at the strychnine-insensitive glycine modulatory site appear to alter the effects of glycine on the NMDA-gated channels. Thus, the data presented here support a mechanism for neuroprotective effects of felbamate via glycine receptor interaction.
- It should be understood that the above Examples is illustrative of the best mode only of the invention herein disclosed.
Claims (6)
- The use of the dicarbamate of 2-phenyl-1,3-propanediol for the manufacture of a medicament for treating and controlling the symptoms of, or for the prevention and control of the neurodegenerative disorders Guam ALS, Parkinsons disease, Alzheimers disease, dementia and lathyrism which are associated with or result from excessive activation of the strychnine-insensitive glycine receptor sites of the N-methyl-D-aspartate receptor complex in human or other warm blooded animal patients.
- A use according to claim 1, wherein the medicament is manufactured in the form of a composition comprising also a pharmaceutical carrier, the composition being in dosage unit form.
- A use according to claim 2, wherein the medicament is manufactured in the form of a gelatin capsule.
- A use according to claim 2, wherein the medicament is manufactured in the form of a tablet.
- A use according to any of claims 1 to 4, wherein the neurodegenerative disorder is Alzheimer's disease.
- A use according to any of claims 1 to 4, wherein the neurodegenerative disorder is Parkinson's disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75374891A | 1991-09-03 | 1991-09-03 | |
US753748 | 2010-04-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0531105A1 EP0531105A1 (en) | 1993-03-10 |
EP0531105B1 true EP0531105B1 (en) | 1997-04-16 |
Family
ID=25031987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92307952A Expired - Lifetime EP0531105B1 (en) | 1991-09-03 | 1992-09-02 | Use of felbamate for the manufacture of a medicament for the treatment of neuropsychopharmacological disorders |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0531105B1 (en) |
AT (1) | ATE151632T1 (en) |
DE (1) | DE69219039T2 (en) |
DK (1) | DK0531105T3 (en) |
ES (1) | ES2103347T3 (en) |
GR (1) | GR3023597T3 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492930A (en) * | 1994-04-25 | 1996-02-20 | Schering Corporation | Method and formulation for treating CNS disorders |
US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0270290A2 (en) * | 1986-11-25 | 1988-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4978680A (en) * | 1989-09-26 | 1990-12-18 | Carter-Wallace, Inc. | Method for the prevention and control of epileptic seizure |
-
1992
- 1992-09-02 EP EP92307952A patent/EP0531105B1/en not_active Expired - Lifetime
- 1992-09-02 AT AT92307952T patent/ATE151632T1/en active
- 1992-09-02 DE DE69219039T patent/DE69219039T2/en not_active Expired - Lifetime
- 1992-09-02 DK DK92307952.9T patent/DK0531105T3/da active
- 1992-09-02 ES ES92307952T patent/ES2103347T3/en not_active Expired - Lifetime
-
1997
- 1997-05-30 GR GR970401240T patent/GR3023597T3/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0270290A2 (en) * | 1986-11-25 | 1988-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
Non-Patent Citations (3)
Title |
---|
Antiepileptic Drugs, Raven Press 1989, p. 572-573 * |
British National Formulary, September 1991, p. 171-182 * |
The Lancet, 20. July 1985, p. 140-143 * |
Also Published As
Publication number | Publication date |
---|---|
DK0531105T3 (en) | 1997-05-12 |
DE69219039D1 (en) | 1997-05-22 |
EP0531105A1 (en) | 1993-03-10 |
ATE151632T1 (en) | 1997-05-15 |
DE69219039T2 (en) | 1997-07-24 |
ES2103347T3 (en) | 1997-09-16 |
GR3023597T3 (en) | 1997-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2081571B1 (en) | MIXED ORL 1/µ AGONISTS FOR TREATING PAIN | |
Bönöczk et al. | Role of sodium channel inhibition in neuroprotection: effect of vinpocetine | |
DE69028542T2 (en) | Felbamat used to treat Lennox-Gastaut syndrome | |
EP0446570B1 (en) | Gabapentin and its derivatives for treating neurodegenerative diseases | |
EP1040830B1 (en) | Remedy for neurodegenerative diseases | |
Gupta et al. | Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease | |
Palmer et al. | Anticonvulsant properties of calcium channel blockers in mice: N‐Methyl‐D‐, L‐Aspartate‐and Bay K 8644‐induced convulsions are potently blocked by the dihydropyridines | |
PT2168585E (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof | |
KR20060124712A (en) | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders | |
US5916925A (en) | Pharmaceutical composition for treatment of dementia | |
EP2892520B1 (en) | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis | |
US20190000863A1 (en) | Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient | |
Peyron et al. | Effects of GABAA receptors activation on brain glucose metabolism in normal subjects and temporal lobe epilepsy (TLE) patients. A positron emission tomography (PET) study Part I: Brain glucose metabolism is increased after GABAA receptors activation | |
EP0531105B1 (en) | Use of felbamate for the manufacture of a medicament for the treatment of neuropsychopharmacological disorders | |
KR100609381B1 (en) | Method for treating cognitive disorders | |
US6194459B1 (en) | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants | |
CA2133427C (en) | Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders | |
Klawans et al. | Supersensitivity to d-amphetamine-and apomorphine-induced stereotyped behavior induced by chronic d-amphetamine administration | |
Martinez-Sanz et al. | Benzothiazepine CGP37157 analogues exert cytoprotection in various in vitro models of neurodegeneration | |
WO2014007853A1 (en) | Dihydromyricetin for the treatment of diseases and disorders of the glutamatergic system | |
Donaldson et al. | Entrainment of circadian rhythms: retinofugal pathways and unilateral suprachiasmatic nucleus lesions | |
Löscher et al. | Effects of the competitive NMDA receptor antagonist, CGP 37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats | |
US5158969A (en) | Indole derivatives as potassium channel blockers | |
CA2159478C (en) | (s)-alpha-phenyl-2-pyridineethanamine (s)-malate and its use as a medicament | |
US5256690A (en) | Method for treating and controlling the symptoms of neurodegenerative disease and neuropsychopharmacological disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17P | Request for examination filed |
Effective date: 19930730 |
|
17Q | First examination report despatched |
Effective date: 19931007 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
ITF | It: translation for a ep patent filed |
Owner name: 0414;01RMFBARZANO' E ZANARDO ROMA S.P.A. |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
REF | Corresponds to: |
Ref document number: 151632 Country of ref document: AT Date of ref document: 19970515 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REF | Corresponds to: |
Ref document number: 69219039 Country of ref document: DE Date of ref document: 19970522 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: 73285 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3023597 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2103347 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 19970715 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
NLT1 | Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1 |
Owner name: MEDPOINTE HEALTHCARE INC. |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: MEDPOINTE HEALTHCARE INC. Free format text: CARTER-WALLACE, INC.#1345 AVENUE OF THE AMERICAS#NEW YORK, N.Y. 10105 (US) -TRANSFER TO- MEDPOINTE HEALTHCARE INC.#265 DAVIDSON AVENUE SUITE 300#SOMERSET, NJ 08873-4120 (US) |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: TE4A Owner name: MEDPOINTE HEALTHCARE INC, US Effective date: 20061219 Ref country code: PT Ref legal event code: PD4A Owner name: MEDPOINTE HEALTHCARE INC., US Effective date: 20061027 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CA |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20100927 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20110926 Year of fee payment: 20 Ref country code: IE Payment date: 20110923 Year of fee payment: 20 Ref country code: MC Payment date: 20110914 Year of fee payment: 20 Ref country code: CH Payment date: 20110923 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20110920 Year of fee payment: 20 Ref country code: GR Payment date: 20110923 Year of fee payment: 20 Ref country code: PT Payment date: 20110901 Year of fee payment: 20 Ref country code: SE Payment date: 20110923 Year of fee payment: 20 Ref country code: AT Payment date: 20110914 Year of fee payment: 20 Ref country code: DE Payment date: 20110923 Year of fee payment: 20 Ref country code: ES Payment date: 20110926 Year of fee payment: 20 Ref country code: FR Payment date: 20110928 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20110929 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20111005 Year of fee payment: 20 Ref country code: BE Payment date: 20110914 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69219039 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69219039 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V4 Effective date: 20120902 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20120902 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20120901 |
|
BE20 | Be: patent expired |
Owner name: *MEDPOINT HEALTHCARE INC. Effective date: 20120902 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 151632 Country of ref document: AT Kind code of ref document: T Effective date: 20120902 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: MA Ref document number: 970401240 Country of ref document: GR Effective date: 20120903 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20120901 Ref country code: DE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20120904 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20120911 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20130708 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20120902 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20120903 |